In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Beam Therapeutics Inc (NASDAQ: BEAM) closed at $17.01 in the last session, up 1.25% from day before closing price of $16.8. In other words, the price has increased by $1.25 from its previous closing price. On the day, 1.53 million shares were traded. BEAM stock price reached its highest trading level at $17.73 during the session, while it also had its lowest trading level at $16.86.
Ratios:
We take a closer look at BEAM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
On March 10, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $40.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’25 when Bellon Christine sold 5,674 shares for $18.35 per share. The transaction valued at 104,122 led to the insider holds 117,294 shares of the business.
Evans John M. sold 30,663 shares of BEAM for $562,684 on Apr 01 ’25. The CEO now owns 986,249 shares after completing the transaction at $18.35 per share. On Apr 01 ’25, another insider, Ciaramella Giuseppe, who serves as the President of the company, sold 7,434 shares for $18.35 each. As a result, the insider received 136,418 and left with 190,216 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 1710474624 and an Enterprise Value of 596417408. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.90 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at 9.381 whereas that against EBITDA is -1.459.
Stock Price History:
The Beta on a monthly basis for BEAM is 2.08, which has changed by -0.24634469 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is -3.86%, while the 200-Day Moving Average is calculated to be -26.63%.
Shares Statistics:
According to the various share statistics, BEAM traded on average about 2.28M shares per day over the past 3-months and 2046990 shares per day over the past 10 days. A total of 100.56M shares are outstanding, with a floating share count of 89.62M. Insiders hold about 10.88% of the company’s shares, while institutions hold 88.04% stake in the company. Shares short for BEAM as of 1749772800 were 21731372 with a Short Ratio of 9.55, compared to 1747267200 on 20844838. Therefore, it implies a Short% of Shares Outstanding of 21731372 and a Short% of Float of 24.299999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Beam Therapeutics Inc (BEAM) in the stock market is under the watchful eye of 14.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.78 and low estimates of -$1.4.
Analysts are recommending an EPS of between -$3.13 and -$5.46 for the fiscal current year, implying an average EPS of -$4.5. EPS for the following year is -$4.48, with 15.0 analysts recommending between -$2.92 and -$5.84.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $13.29M. It ranges from a high estimate of $25M to a low estimate of $7.47M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $11.77MFor the next quarter, 11 analysts are estimating revenue of $14.58M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $7.47M.
A total of 15 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $110M, while the lowest revenue estimate was $29.88M, resulting in an average revenue estimate of $55.4M. In the same quarter a year ago, actual revenue was $63.52MBased on 15 analysts’ estimates, the company’s revenue will be $55.29M in the next fiscal year. The high estimate is $160M and the low estimate is $80k.
